Please upgrade your browser.
Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): Results of phase III AXIS trial.
Therapy directed at a particular molecular aberration in a patient's tumor resulted in higher response rates and extended time to treatment failure compared with standard of care in a phase I trial.
Despite the proliferation of biomarkers for many aspects of renal cell carcinoma (RCC), none have been approved for routine clinical use by the U.S. Food and Drug Administration (FDA). This has provided an opportunity for the exploration of a wide variety of biomarkers in RCC.
Richard L. Schilsky, MD, Past ASCO President, Professor of Medicine and Chief, Section of Hematology-Oncology, University of Chicago Pritzker School of Medicine, and Deputy Director, Comprehensive Cancer Center, University of Chicago .
Finding Could Affect Patient Treatment Options
The 2011 ASCO Annual Meeting is being held this week in Chicago
AVEO is initially receiving $15 million. Under the terms of the license agreement, AVEO will receive the first half of this amount as an up-front payment from Centocor Ortho Biotech.
Pfizer says it asked European Union to approve its kidney cancer drug candidate axitinib
Oregon Health & Science University Knight Cancer Institute researchers uncovered a gene that may be the key to helping kidney cancer patients who don't respond to current therapies.
|Powered by NeonCRM|